期刊文献+

以泛蛋白为中介的蛋白质降解的发现——2004年诺贝尔化学奖研究成果介绍 被引量:1

原文传递
导出
摘要 10月 6日瑞典皇家科学院宣布将 2 0 0 4年诺贝尔化学奖授予以色列科学家阿龙 -西查诺瓦、阿弗拉姆-赫尔什科和美国科学家伊尔温 -罗斯 ,以表彰他们在蛋白质调节系统方面的重大发现。本刊编辑部把诺贝尔基金会官方网站中公布的获奖成果详细评述文章译出并转载于此 。
作者 公鲁
出处 《化学通报》 CAS CSCD 北大核心 2004年第11期789-794,共6页 Chemistry
  • 相关文献

同被引文献36

  • 1Adams J. Development of the proteasome inhibitor PS-341.Oneologist, 2002, 7:9-16.
  • 2Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004, 22:304-311.
  • 3Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res, 2003, 9:6316-6325.
  • 4Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002,277:16639-16647.
  • 5Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene,2001,20:4519-4527.
  • 6Yang Y, Ikezoe T, Saito T, et al. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci, 2004, 95:176-180.
  • 7Cusack Jc Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappa B inhibition. Cancer Res, 2001, 61 :3535 -3540.
  • 8Aghajanian C, Soignet S, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.Clin Cancer Res, 2002, 8: 2505-2511.
  • 9Orlowski, RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol, 2002, 20: 4420-4427.
  • 10Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growths, induces apoptosis , and overcomes drug resistance in human multiple myeloma cells. Cancer Res,2001,61 : 3071-3076.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部